Applying Hsp104 to protein-misfolding disorders
- PMID: 20130674
- PMCID: PMC2933416
- DOI: 10.1139/o09-121
Applying Hsp104 to protein-misfolding disorders
Abstract
Hsp104, a hexameric AAA+ ATPase found in yeast, transduces energy from cycles of ATP binding and hydrolysis to resolve disordered protein aggregates and cross-beta amyloid conformers. These disaggregation activities are often co-ordinated by the Hsp70 chaperone system and confer considerable selective advantages. First, renaturation of aggregated conformers by Hsp104 is critical for yeast survival after various environmental stresses. Second, amyloid remodeling by Hsp104 enables yeast to exploit multifarious prions as a reservoir of beneficial and heritable phenotypic variation. Curiously, although highly conserved in plants, fungi and bacteria, Hsp104 orthologues are absent from metazoa. Indeed, metazoan proteostasis seems devoid of a system that couples protein disaggregation to renaturation. Here, we review recent endeavors to enhance metazoan proteostasis by applying Hsp104 to the specific protein-misfolding events that underpin two deadly neurodegenerative amyloidoses. Hsp104 potently inhibits Abeta42 amyloidogenesis, which is connected with Alzheimer's disease, but appears unable to disaggregate preformed Abeta42 fibers. By contrast, Hsp104 inhibits and reverses the formation of alpha-synuclein oligomers and fibers, which are connected to Parkinson's disease. Importantly, Hsp104 antagonizes the degeneration of dopaminergic neurons induced by alpha-synuclein misfolding in the rat substantia nigra. These studies raise hopes for developing Hsp104 as a therapeutic agent.
Figures


Similar articles
-
Purification of hsp104, a protein disaggregase.J Vis Exp. 2011 Sep 30;(55):3190. doi: 10.3791/3190. J Vis Exp. 2011. PMID: 21989490 Free PMC article.
-
Operational plasticity enables hsp104 to disaggregate diverse amyloid and nonamyloid clients.Cell. 2012 Nov 9;151(4):778-793. doi: 10.1016/j.cell.2012.09.038. Cell. 2012. PMID: 23141537 Free PMC article.
-
Regulation of the Hsp104 middle domain activity is critical for yeast prion propagation.PLoS One. 2014 Jan 23;9(1):e87521. doi: 10.1371/journal.pone.0087521. eCollection 2014. PLoS One. 2014. PMID: 24466354 Free PMC article.
-
Applying chaperones to protein-misfolding disorders: molecular chaperones against α-synuclein in Parkinson's disease.Int J Biol Macromol. 2013 Sep;60:196-205. doi: 10.1016/j.ijbiomac.2013.05.032. Epub 2013 Jun 5. Int J Biol Macromol. 2013. PMID: 23748003 Review.
-
Engineering enhanced protein disaggregases for neurodegenerative disease.Prion. 2015;9(2):90-109. doi: 10.1080/19336896.2015.1020277. Prion. 2015. PMID: 25738979 Free PMC article. Review.
Cited by
-
Prion-like disorders: blurring the divide between transmissibility and infectivity.J Cell Sci. 2010 Apr 15;123(Pt 8):1191-201. doi: 10.1242/jcs.051672. J Cell Sci. 2010. PMID: 20356930 Free PMC article.
-
The metazoan protein disaggregase and amyloid depolymerase system: Hsp110, Hsp70, Hsp40, and small heat shock proteins.Prion. 2013 Nov-Dec;7(6):457-63. doi: 10.4161/pri.27531. Epub 2014 Jan 8. Prion. 2013. PMID: 24401655 Free PMC article.
-
Potentiated Hsp104 variants suppress toxicity of diverse neurodegenerative disease-linked proteins.Dis Model Mech. 2014 Oct;7(10):1175-84. doi: 10.1242/dmm.016113. Epub 2014 Jul 25. Dis Model Mech. 2014. PMID: 25062688 Free PMC article.
-
AAA+ Protein-Based Technologies to Counter Neurodegenerative Disease.Biophys J. 2019 Apr 23;116(8):1380-1385. doi: 10.1016/j.bpj.2019.03.007. Epub 2019 Mar 22. Biophys J. 2019. PMID: 30952364 Free PMC article. Review.
-
Mapping the degradation pathway of a disease-linked aspartoacylase variant.PLoS Genet. 2021 Apr 29;17(4):e1009539. doi: 10.1371/journal.pgen.1009539. eCollection 2021 Apr. PLoS Genet. 2021. PMID: 33914734 Free PMC article.
References
-
- Anfinsen CB. Principles that govern the folding of protein chains. Science. 1973;181(96):223–230. doi:10.1126/science.181.4096.223. PMID:4124164. - PubMed
-
- Arimon M, Grimminger V, Sanz F, Lashuel HA. Hsp104 targets multiple intermediates on the amyloid pathway and suppresses the seeding capacity of Abeta fibrils and protofibrils. J. Mol. Biol. 2008;384(5):1157–1173. doi:10.1016/j.jmb.2008.09.063. PMID:18851977. - PubMed
-
- Arrasate M, Mitra S, Schweitzer ES, Segal MR, Finkbeiner S. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature. 2004;431(7010):805–810. doi:10.1038/nature02998. PMID:15483602. - PubMed
-
- Bainbridge JW, Smith AJ, Barker SS, Robbie S, Henderson R, Balaggan K, et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. N. Engl. J. Med. 2008;358(21):2231–2239. doi:10.1056/NEJMoa0802268. PMID:18441371. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Molecular Biology Databases